Loading company…
Toronto diagnostics company developing the Veridapt DX biomarker test, which measures tumour response to cancer treatment within weeks.
Rna Diagnostics Inc. was founded in 2010 and is headquartered in Toronto, Canada. Its Veridapt DX predictive biomarker platform monitors ribosomal RNA disruption in tumour cells, giving early insight into response to neoadjuvant treatment, mainly for breast cancer patients. It is validated in the BREVITY clinical trial across seven countries. Revenue comes from clinical laboratory sales billed to hospitals and oncology clinics. The company closed a USD 4.000 mn Series A round led by NovaQuest Capital Management on July 4, 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in